These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36901764)

  • 1. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.
    Barrios-Bernal P; Lucio-Lozada J; Ramos-Ramírez M; Hernández-Pedro N; Arrieta O
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
    da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
    Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
    J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteoloside induces G
    Zhou M; Shen S; Zhao X; Gong X
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAK and PI3K pathway activation confers resistance to KRAS
    Chan CH; Chiou LW; Lee TY; Liu YR; Hsieh TH; Yang CY; Jeng YM
    Br J Cancer; 2023 Jan; 128(1):148-159. PubMed ID: 36319849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
    de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
    Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
    Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delicaflavone induces autophagic cell death in lung cancer via Akt/mTOR/p70S6K signaling pathway.
    Sui Y; Yao H; Li S; Jin L; Shi P; Li Z; Wang G; Lin S; Wu Y; Li Y; Huang L; Liu Q; Lin X
    J Mol Med (Berl); 2017 Mar; 95(3):311-322. PubMed ID: 27838742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.
    Hondo N; Kitazawa M; Koyama M; Nakamura S; Tokumaru S; Miyazaki S; Kataoka M; Seharada K; Soejima Y
    Cancer Lett; 2023 Jul; 567():216264. PubMed ID: 37336286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.
    Kim D; Min D; Kim J; Kim MJ; Seo Y; Jung BH; Kwon SH; Ro H; Lee S; Sa JK; Lee JY
    J Exp Clin Cancer Res; 2023 Dec; 42(1):338. PubMed ID: 38093368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
    Mohanty A; Nam A; Srivastava S; Jones J; Lomenick B; Singhal SS; Guo L; Cho H; Li A; Behal A; Mirzapoiazova T; Massarelli E; Koczywas M; Arvanitis LD; Walser T; Villaflor V; Hamilton S; Mambetsariev I; Sattler M; Nasser MW; Jain M; Batra SK; Soldi R; Sharma S; Fakih M; Mohanty SK; Mainan A; Wu X; Chen Y; He Y; Chou TF; Roy S; Orban J; Kulkarni P; Salgia R
    Sci Adv; 2023 Oct; 9(41):eade3816. PubMed ID: 37831779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.